Back to homepage

Immunology

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Authors: Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

More▸

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Authors: Paolo Antonio Ascierto MD, Dirk Schadendorf MD, PhD

This article provides background on NMSC and describes
the updates and new perspectives that were discussed during
the symposium ‘CSCC It Bridge’ held in Naples, Italy, 28–29
November 2018.

More▸

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports

Authors: José Alexandre Mendonça PhD, Guilherme B Damian MD

This series of case reports demonstrates the
efficacy of certolizumab pegol in patients with rheumatoid arthritis using gray scale
and power Doppler ultrasonography to monitor disease progression.

More▸

Severe refractory asthma: current treatment options and ongoing research

Authors: Francesco Menzella MD, Francesca Bertolini MSc, PhD, Mirella Biava MSc, Carla Galeone MSc, Chiara Scelfo MD, Marco Caminati MD

In this review, the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice are discussed.

More▸

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Authors: Daniela Opris-Belinski MD, PhD, Shandor F Erdes MD, PhD, Simeon Grazio MD, PhD, Ladislav Šenolt MD, PhD, Maja Hojnik MD, PhD, Orsolya Nagy MD, PhD, Diana Marina BSc, Sándor Szántó MD, PhD, DSc

This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis in five Central and Eastern Europe countries.

More▸